2022
Conventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials
Shoji S, Kohsaka S, Shiraishi Y, Kohno T, Sawano M, Ikemura N, Niimi N, Nagatomo Y, Tanaka T, Takei M, Ono T, Sakamoto M, Nakano S, Nakamura I, Inoue S, Fukuda K, Yoshikawa T. Conventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials. International Journal Of Cardiology 2022, 359: 76-83. PMID: 35421518, DOI: 10.1016/j.ijcard.2022.04.020.Peer-Reviewed Original ResearchConceptsConventional medical therapyHF readmission ratesMedical therapy useMedical therapyLong-term outcomesEnrollment criteriaReadmission ratesTherapy useRecent trialsReduced ejection fractionHeart failure patientsHeart failure treatmentUse of BBsShift trialsDAPA-HFHF registryHFrEF patientsMulticenter registryPARADIGM-HFFailure patientsConsecutive patientsEjection fractionPatient subsetsPrescription ratesFailure treatment
2014
Prognostic Implication of Physical Signs of Congestion in Acute Heart Failure Patients and Its Association with Steady-State Biomarker Levels
Negi S, Sawano M, Kohsaka S, Inohara T, Shiraishi Y, Kohno T, Maekawa Y, Sano M, Yoshikawa T, Fukuda K. Prognostic Implication of Physical Signs of Congestion in Acute Heart Failure Patients and Its Association with Steady-State Biomarker Levels. PLOS ONE 2014, 9: e96325. PMID: 24802880, PMCID: PMC4011709, DOI: 10.1371/journal.pone.0096325.Peer-Reviewed Original ResearchConceptsJugular venous distensionAcute heart failurePulmonary ralesTime of dischargePhysical findingsReadmission ratesAHF patientsAcute heart failure patientsElevated troponin T levelsSingle-center university hospitalConsecutive AHF patientsElevated TnT levelsParoxysmal nocturnal dyspneaNon-ischemic etiologyTroponin T levelsHeart failure patientsNon-ischemic cardiomyopathyLong-term outcomesTime of admissionThird heart soundNocturnal dyspneaMean followPrimary endpointVenous distensionFailure patients